Contact PD/PI: Sherwin, Robert S. 1. Overall Project Summary- The Yale Center for Clinical Investigation (YCCI) was created in 2005 to strengthen Yale's infrastructure for clinical and translational research, based on the recommendation of a Medical School strategic planning committee. Soon afterwards, when NIH launched its new program of Clinical & Translational Science Awards, YCCI applied and became the home of the Yale CTSA. Since then, one of its major priorities has been to support the education and career development of the next generation of clinical and translational investigators. As described in the present application, this initiative has met with great success, underscored by the fact that graduates of YCCI's K-Scholar program have received 47 individual NIH K Awards, 43 NIH RO1 awards, and 65 Foundation grants, published >1,800 papers, and obtained >$240 million in independent research funding. Remarkably, 98% of the program's graduates have stayed in academic medicine or pursued research careers in the biotech or pharmaceutical industries. YCCI has also made substantial progress in its push to accelerate the translation of disease-related discoveries into the clinic. As will be described, it provides Yale investigators with key assistance in areas including biostatistics and bioinformatics, study design, protocol development, regulatory approval, patient recruitment, access to inpatient and outpatient research facilities, and budgeting support, and gives them ready access to pilot grants and state-of-the-art research cores. The result has been a significant upsurge in the number and scope of clinical research projects throughout the Medical Center. In the next grant cycle, YCCI will build upon these achievements with an emphasis on team-based T1 to T4 research, including studies across the lifespan. YCCI will also pursue new partnerships with the Yale School of Engineering & Applied Science to develop an innovative technology transfer program called the Center for Biological and Innovative Technology (CBIT) and with the School of Organization & Management to offer a novel program of leadership training for clinicians and physician-scientists. In addition, YCCI will take active advantage of the recent expansion of clinical services by Yale-New Haven Hospital (YNHH), which now has 1,540 beds and more than 1 million outpatients visits per year, and the growth of the Yale Medical Group (YMG), which has a network of >1,200 practicing physicians in >100 clinical specialties. The resulting clinical volume (~4 million patient records) gives Yale researchers access to a large, diverse patient base for outcomes studies and clinical trials. Overall, YCCI will leverage Yale's outstanding scientific and clinical environment and work with other CTSA hubs to foster the growth of multidisciplinary team science, to develop innovative strategies for disease prevention, diagnostics, and therapeutics, and to implement results for the benefit of the health care system and the population as a whole. Project Summary/Abstract Page 220 Contact PD/PI: Sherwin, Robert S. Program Narrative Yale Center for Clinical Investigation (YCCI) is a leader in team-based T1 to T4 research, including studies across the lifespan. YCCI will leverage Yale University's outstanding scientific and clinical environment and work with other CTSA hubs to foster the growth of multidisciplinary team science, to develop innovative strategies for disease prevention, diagnostics, and therapeutics, and to implement results for the benefit of the health care system and the population as a whole.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
3UL1TR001863-02S2
Application #
9444117
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Merchant, Carol
Project Start
2016-07-01
Project End
2021-05-31
Budget Start
2017-08-22
Budget End
2018-05-31
Support Year
2
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Curtis, Brian R; Hsu, Yen-Michael S; Podoltsev, Nikolai et al. (2018) Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies. Blood 131:1486-1489
Foss, Francine Marie; Parker, Terri (2018) A Phase I Dose-Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low-Grade or Intermediate-Grade B-Cell or T-Cell Lymphoma. Oncologist 23:397-e30
Rattray, Nicholas J W; Deziel, Nicole C; Wallach, Joshua D et al. (2018) Beyond genomics: understanding exposotypes through metabolomics. Hum Genomics 12:4
Woodberry, Kristen A; Seidman, Larry J; Bryant, Caitlin et al. (2018) Treatment Precedes Positive Symptoms in North American Adolescent and Young Adult Clinical High Risk Cohort. J Clin Child Adolesc Psychol 47:69-78
Davis, Lori L; Kyriakides, Tassos C; Suris, Alina M et al. (2018) Effect of Evidence-Based Supported Employment vs Transitional Work on Achieving Steady Work Among Veterans With Posttraumatic Stress Disorder: A Randomized Clinical Trial. JAMA Psychiatry 75:316-324
Yang, Daniel X; Soulos, Pamela R; Davis, Brigette et al. (2018) Impact of Widespread Cervical Cancer Screening: Number of Cancers Prevented and Changes in Race-specific Incidence. Am J Clin Oncol 41:289-294
Lu, Yuan; Wang, Pei; Zhou, Tianna et al. (2018) Comparison of Prevalence, Awareness, Treatment, and Control of Cardiovascular Risk Factors in China and the United States. J Am Heart Assoc 7:
Joseph, Anne M; Rothman, Alexander J; Almirall, Daniel et al. (2018) Lung Cancer Screening and Smoking Cessation Clinical Trials. SCALE (Smoking Cessation within the Context of Lung Cancer Screening) Collaboration. Am J Respir Crit Care Med 197:172-182
Meisel, Matthew K; Kenney, Shannon R; Barnett, Nancy P (2018) Characteristics of prospectively identified negative alcohol-related events among college students. Addict Behav 78:138-144
van Duin, David; Lok, Judith J; Earley, Michelle et al. (2018) Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis 66:163-171

Showing the most recent 10 out of 2558 publications